Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, November 28, 2023
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
[ Tue, Nov 28th 2023
] - WOPRAI
Mon, November 27, 2023
[ Mon, Nov 27th 2023
] - WOPRAI
[ Mon, Nov 27th 2023
] - WOPRAI
[ Mon, Nov 27th 2023
] - WOPRAI
[ Mon, Nov 27th 2023
] - WOPRAI
[ Mon, Nov 27th 2023
] - WOPRAI
[ Mon, Nov 27th 2023
] - WOPRAI
[ Mon, Nov 27th 2023
] - WOPRAI
[ Mon, Nov 27th 2023
] - WOPRAI
[ Mon, Nov 27th 2023
] - WOPRAI
[ Mon, Nov 27th 2023
] - WOPRAI
[ Mon, Nov 27th 2023
] - WOPRAI
Arthur He Reiterated (CALT) at Strong Buy and Held Target at $50 on, Nov 27th, 2023
Arthur He of HC Wainwright & Co., Reiterated "Calliditas Therapeutics AB (publ)" (CALT) at Strong Buy and Held Target at $50 on, Nov 27th, 2023.
Arthur has made no other calls on CALT in the last 4 months.
There are 2 other peers that have a rating on CALT. Out of the 2 peers that are also analyzing CALT, 1 agrees with Arthur's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Vamil Divan of "Guggenheim" Maintained at Hold with Decreased Target to $18 on, Friday, August 18th, 2023
This is the rating of the analyst that currently disagrees with Arthur
- Edwin Zhang of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $50 on, Monday, October 16th, 2023
